In the present study, these three beneficial effects would be anticipated to be enhanced by TEMT in those AD subjects who had low baseline GCSF levels in CSF, all of whom showed TEMT-induced increases in CSF levels of GCSF. The gene discussed is CSF3; the disease is Alzheimer disease.